Australia's most trusted
source of pharma news
Saturday, 06 September 2025
Posted 5 September 2025 AM
An Australian invention is helping pharmas navigate the complex sales environment for specialty treatments used in rare diseases that are delivered in hospitals.
Industry veteran Ben Manuele started Samson Specialty to solve the problems he encountered during 17 years in the pharma industry with Novartis and Pfizer, and rising to Director of Sales ANZ for Actelion, which was later bought by Johnson & Johnson.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.